Dengue Author: Suranjith L. Seneviratne, MD, DPhil, MRCP, FRCPath; Panduka Karunanayake, MD, MRCP; Bandula Wijesiriwardena, MD, FRCP, FCCP, FCMSA, FRACP, FACP
Editorial changes - 2009-11-13
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up
Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools
Drug Therapy
  • Use appropriate drugs to manage symptoms of dengue.
  • Avoid medications that have not been found to be beneficial in patients with dengue.
Drug Treatment for Dengue (table)

Use appropriate drugs to manage symptoms of dengue.C

  • Administer supportive drug therapy as indicated, including:
    • Acetaminophen or opiates for analgesia as needed
    • Acetaminophen for fever
    • Domperidone, 10 mg intravenously three times a day, in adults for nausea and vomiting
    • Diazepam, 0.5 mg/kg rectally, in patients with encephalopathy and seizures
    • Ranitidine, 1 mg/kg every 8 hours (50 mg intravenously every 8 hours in adults), or pantoprazole, 40 mg once daily, for upper gastrointestinal bleeding
    • Sedatives and anxiolytics as indicated for agitation
  • Use antibacterial therapy, antiparasitic therapy, or both until the diagnosis of dengue is confirmed or excluded or when a secondary infection is suspected, following appropriate local medication guidelines.
  • Consider administration of vasopressors in patients with myocarditis who are hemodynamically unstable despite receiving adequate fluid replacement.
  • Avoid the use of salicylates, NSAIDs, heparin, or other medications that may promote bleeding during the acute illness.
  • See table Drug Treatment for Dengue.
  • See table Crystalloids, Colloids, and Blood Products for the Treatment of Dengue.
Background | Back to top


Avoid medications that have not been found to be beneficial in patients with dengue.B

Background | Back to top

FAQs
Bandula Wijesiriwardena, MD, FRCP, FCCP, FCMSA, FRACP, FACP has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Panduka Karunanayake, MD, MRCP has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Suranjith L. Seneviratne, MD, DPhil, MRCP, FRCPath has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.

The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.